In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CardioDx brings in $57.5mm so far through its Series E round

Executive Summary

CardioDx Inc. (cardiovascular diagnostics) has raised $57.5mm through its Series E venture round. New backer Longitude Capital led (and contributes a board member) and was joined by current shareholders Kleiner Perkins Caufield & Byers, TPG, MDV, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group, GE Capital, and eight other undisclosed investors. According to CardioDx’s Form D filing, it may bring in another $20.8mm before closing the financing.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies